An innovative filtration system to improve the coagulation properties of plasma...
An innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleeding
Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a rat...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ClearPlasma
ClearPlasma is an innovative medical device that enhances co...
71K€
Cerrado
JCI-2011-10417
ROLE OF PLATELET-PROTEIN S IN THROMBUS STABILIZATION
96K€
Cerrado
PID2020-117265GB-I00
TERAPIAS BASADAS EN PLAQUETAS: TRANSFUSION, TROMBOPROFILAXIS...
158K€
Cerrado
Smart Clot
SmartClot Personalized platform for the combined evaluation...
71K€
Cerrado
PTQ-10-02731
Caracterización, estabilidad, desarrollo analítico y preclín...
25K€
Cerrado
Información proyecto ClearPlasma
Duración del proyecto: 12 meses
Fecha Inicio: 2022-07-27
Fecha Fin: 2023-07-31
Líder del proyecto
PLASFREE LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a ratio of 1:1:1; however, this can lead to increased bleeding
and death. PlasFree is tackling this unmet demand of novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding. ClearPlasma™ also allows to reduce up
to 45% of the number of plasma units required during transfusion. PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion. With the EIC support, PlasFree aims to deliver substantial global impact, for patients and healthcare systems, by accelerating the
development of ClearPlasma™ as well as scaling-up and conducting clinical validation to prove the device’s safety and efficacy.